KU; Mannching Sherry

Patent Applications and Registrations

Patent applications and USPTO patent grants for KU; Mannching Sherry.The latest application filed is for "methods for producing particles of an active ingredient".

Company Profile

1.21.37

KU; Mannching Sherry - Thiells NY
KU; Mannching Sherry - Burbank CA
Ku; Mannching Sherry - New York NY

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Methods For Producing Particles Of An Active Ingredient App 20210015752 - CHEN; Yan-Ming ; et al.	2021-01-21
Preparation Of Microparticles Of An Active Ingredient App 20190380967 - LIU; Amy ; et al.	2019-12-19
Expression Construct And Method For Producing Proteins Of Interest App 20190352365 - YANG; Shu-Ping ; et al.	2019-11-21
Maleate salts of (E)-N-{4[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quino- linyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof Grant 10,035,788 - Lu , et al. July 31, 2	2018-07-31
Maleate Salts Of (e)-n--4-(dimethylamino)-2-butenamide And Crystalline Forms Thereof App 20170320852 - Lu; Quinhong ; et al.	2017-11-09
Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quin- olinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof Grant 9,630,946 - Lu , et al. April 25, 2	2017-04-25
Maleate Salts Of (e)-n--4-(dimethylamino)-2-butenamide And Crystalline Forms Thereof App 20160068511 - Lu; Quinhong ; et al.	2016-03-10
Maleate salts of (E)-N-{4-[3-Chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quin- olinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof Grant 9,139,558 - Lu , et al. September 22, 2	2015-09-22
Methods and compositions for treating hyperuricemia and metabolic disorders associated with hyperuricemia Grant 8,865,689 - Ku , et al. October 21, 2	2014-10-21
Methods of decreasing glycosylated hemoglobin in patients with dyslipidemia Grant 8,846,758 - Ku , et al. September 30, 2	2014-09-30
Maleate Salts Of (e)-n--4-(dimethylamino)-2-butenamide And Crystalline Forms Thereof App 20130281488 - Lu; Quinhong ; et al.	2013-10-24
Methods of using diacerein as an adjunctive therapy for diabetes Grant 8,536,152 - Ku , et al. September 17, 2	2013-09-17
Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quin- olinyl)-4-(dimethylamino)-2-buteramide and crystalline forms thereof Grant 8,394,959 - Lu , et al. March 12, 2	2013-03-12
Crystalline solid forms of tigecycline and methods of preparing same Grant 8,372,995 - Krishnan , et al. February 12, 2	2013-02-12
Methods Of Decreasing Glycosylated Hemoglobin In Patients With Dyslipidemia App 20130022610 - Ku; Mannching Sherry ; et al.	2013-01-24
Maleate Salts of (E)-N--4-(Dimethylamino)-2-Butenamide and Crystalline Forms Thereof App 20120289545 - Lu; Qinghong ; et al.	2012-11-15
Methods And Compositions For Treating Hyperuricemia And Metabolic Disorders Associated With Hyperuricemia App 20120232044 - Ku; Mannching Sherry ; et al.	2012-09-13
Methods of treating .alpha.v.beta.3 integrin-associated diseases by administering polypeptides selective for .alpha.v.beta.3 integrin Grant 8,183,201 - Chuang , et al. May 22, 2	2012-05-22
Polymorph Form II of Tanaproget App 20120115858 - Tesconi; Marc Sadler ; et al.	2012-05-10
Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quin- olinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof Grant 8,173,814 - Lu , et al. May 8, 2	2012-05-08
Polymorph form II of tanaproget Grant 8,114,869 - Tesconi , et al. February 14, 2	2012-02-14
Maleate Salts Of (e)-n--4-(dimethylamino)-2-butenamide And Crystalline Forms Thereof App 20110313166 - LU; Qinghong ; et al.	2011-12-22
Methods of Using Diacerein as an Adjunctive Therapy for Diabetes App 20110251155 - Ku; Mannching Sherry ; et al.	2011-10-13
Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quin- olinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof Grant 8,022,216 - Lu , et al. September 20, 2	2011-09-20
Polymorph Form II of Tanaproget App 20110212953 - Tesconi; Marc Sadler ; et al.	2011-09-01
Polypeptides Selective for avB3 Integrin, Including Pegylated Polypeptides, And Pharmaceutical Uses Thereof App 20110166072 - Chuang; Woei-Jer ; et al.	2011-07-07
Process for preparing polymorph form II of tanaproget Grant 7,968,709 - Tesconi , et al. June 28, 2	2011-06-28
Polymorph Form II of Tanaproget App 20100267715 - Tesconi; Marc Sadler ; et al.	2010-10-21
Polymorphs Of N2-(1,1'-biphenyl-4-ylcarbonyl)-n1-[2-(4-fluorophenyl)-1,1-dimethylethyl]- -l-alpha-glutamine App 20100216886 - Wang; Qiuxia ; et al.	2010-08-26
Polymorph form II of tanaproget Grant 7,759,341 - Tesconi , et al. July 20, 2	2010-07-20
Liquid Formulations Of Phospholipase Enzyme Inhibitors App 20100113443 - Ku; Mannching Sherry ; et al.	2010-05-06
Crystal Forms Of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol App 20100113541 - TADAYON; Abdolsamad ; et al.	2010-05-06
Semi-solid Formulations Of Phospholipase Enzyme Inhibitors App 20100093725 - Ku; Mannching Sherry ; et al.	2010-04-15
Crystal forms of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol Grant 7,683,182 - Tadayon , et al. March 23, 2	2010-03-23
Liquid Formulations Of Phospholipase Enzyme Inhibitors App 20100069385 - Donahue; Frances Anne ; et al.	2010-03-18
Formulations Of Phospholipase Enzyme Inhibitors App 20100056520 - Donahue; Frances Anne ; et al.	2010-03-04
Maleate Salts Of (e)-n--4-(dimethylamino)-2-butenamide And Crystalline Forms Thereof App 20090176827 - Lu; Qinghong ; et al.	2009-07-09
Synthesis and characterization of polymorph form II of 4-(2-(4,4-dimethyl-2-oxooxazolidin-3-YL)thiazol-4-YL)benzonitrile App 20080234340 - Mirmehrabi; Mahmoud ; et al.	2008-09-25
Crystalline forms of 5-chloro-6-{2,6-difluoro-4-[3-(methylamino)propoxy]phenyl}-N-[(1S)-2,2,2-- trifluoro-1-methylethyl][1,2,4]triazolo[1,5-a]pyrimidin-7-amine salts Grant 7,419,982 - Qi , et al. September 2, 2	2008-09-02
Controlled-release formulation of piperazine-piperidine antagonists and agonists of the 5-HT1A receptor having enhanced intestinal dissolution App 20080199518 - Ku; Mannching Sherry ; et al.	2008-08-21
Pharmaceutical Compositions Containing Substituted Indole Acid Derivatives As Inhibitors Of Plasminogen Activator Inhibitor-1 (pai-1) App 20080188540 - Tesconi; Marc Sadler ; et al.	2008-08-07
Pharmaceutical Compositions Containing Substituted Indole Acid Derivatives As Inhibitors Of Plasminogen Activator Inhibitor-1 (pai-1) App 20080188543 - THAKUR; Arun A. ; et al.	2008-08-07
Novel Indole Polymorphs App 20080188542 - TADAYON; Abdolsamad ; et al.	2008-08-07
Aqueous Pharmaceutical Formulations of ER-beta Selective Ligands App 20070191442 - TESCONI; MARC S. ; et al.	2007-08-16
Pharmaceutical Formulations Containing 5-cyclopropyl-2-(4-fluorophenyl)-6-[(2-hydroxyethyl)(methylsulfonyl)amino- ]-n-methyl-1-benzofuran-3-carboxamide And Method Of Making The Same App 20070128270 - Ku; Mannching Sherry ; et al.	2007-06-07
Crystalline solid forms of tigecycline and methods of preparing same App 20070123497 - Krishnan; Lalitha ; et al.	2007-05-31
Polymorph form II of tanaproget App 20060247235 - Tesconi; Marc Sadler ; et al.	2006-11-02
Crystal forms of 2-(3-Fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazole-5-ol App 20060205798 - Tadayon; Abdolsamad ; et al.	2006-09-14
Formulations of substituted benzoxazoles App 20060121110 - Provost; James A. ; et al.	2006-06-08
Formulations of substituted benzoxazoles App 20060121111 - Zhuang; Kai ; et al.	2006-06-08
Formulations of substituted benzoxazoles App 20060121109 - Rowley; Michael J. ; et al.	2006-06-08
Formulations of [1,4]diazepino[6,7,1-IJ]quinoline derivatives App 20060110451 - Lin; Yanning ; et al.	2006-05-25

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.